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Abstract
Aims The role of microRNAs has not been studied in cardiogenic shock. We examined the potential role of miR-423-5p level
to predict mortality and associations of miR-423-5p with prognostic markers in cardiogenic shock.
Methods and results We conducted a prospective multinational observational study enrolling consecutive cardiogenic shock
patients. Blood samples were available for 179 patients at baseline to determine levels of miR-423-5p and other biomarkers.
Patients were treated according to local practice. Main outcome was 90 day all-cause mortality. Median miR-423-5p level was
significantly higher in 90 day non-survivors [median 0.008 arbitrary units (AU) (interquartile range 0.003–0.017) vs. 0.004 AU
(0.002–0.009), P = 0.003]. miR-423-5p level above median was associated with higher lactate (median 3.7 vs. 2.4 mmol/L,
P = 0.001) and alanine aminotransferase levels (median 68 vs. 35 IU/L, P < 0.001) as well as lower cardiac index (1.8 vs.
2.4, P = 0.04) and estimated glomerular filtration rate (56 vs. 70 mL/min/1.73 m2, P = 0.002). In Cox regression analysis,
miR-423-5p level above median was associated with 90 day all-cause mortality independently of established risk factors of car-
diogenic shock [adjusted hazard ratio 1.9 (95% confidence interval 1.2–3.2), P = 0.01].
Conclusions In cardiogenic shock patients, above median level of miR-423-5p at baseline is associated with markers of hy-
poperfusion and seems to independently predict 90 day all-cause mortality.
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Introduction
Cardiogenic shock (CS) is a severe state of inadequate sys-
temic tissue perfusion due to low cardiac output, often
resulting in multi-organ failure.1 In-hospital mortality is close
to 40% even with current treatment.2 More research is
needed to understand the mechanisms leading to shock
and hypoperfusion and to discover new biomarkers to opti-
mize treatment for each patient.
MicroRNAs (miRNAs) are short non-coding RNAs that have
a central role in regulating gene expression. miRNAs can be
detected in plasma, body fluids, and tissues.3 Circulating
miRNAs have emerged as potential diagnostic and prognostic
biomarkers of cardiovascular disease.4 In previous studies on
miRNAs in heart failure, miR-423-5p is one of the miRNAs
most consistently shown to be associated with the diagnosis
and prognosis of heart failure,5–8 although discrepancies ex-
ist.9–11 Induction of apoptosis by miR-423-5p has been shown
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in cardiomyocytes,12 suggesting that miR-423-5p may also
have a role in the pathogenesis and progression of heart dis-
eases. Indeed, miR-423-5p was reported to be up-regulated
in failing human myocardium.13
Aims
As there are no studies on microRNAs in CS, we chose to
examine the potential of miR-423-5p level to predict
mortality and the possible associations of miR-423-5p with
prognostic markers in CS.
Materials and methods
This study was part of a predefined biomarker substudy of
the CardShock study. The CardShock study (ClinicalTrials.gov
identifier: NCT01374867) was a multicenter, prospective,
observational study enrolling patients within 6 h of the
detection of CS (for details, see Harjola et al.2). The study
was approved by the local ethics committees and conducted
in accordance with the Declaration of Helsinki. Written
informed consent was received from all patients or their next
of kin. Patients were treated according to local practice, and
treatment and procedures were registered. Of the 219
patients recruited for the CardShock study, blood samples
were available at baseline for 179 patients (2 centres did
not participate in the biomarker substudy), and at 24 h for
142 patients (22 patients died before this time point, and
18 patients had missing samples). Pulmonary artery catheter
use was at the discretion of the treating physician and was
used in 37 patients to measure the cardiac output using the
thermodilution method, from which the cardiac index was
calculated.
Blood samples were collected into ethylenediaminetetra-
acetic acid tubes at study enrolment. Total RNA was
extracted from plasma samples, and miR-423-5p level was
assessed by quantitative PCR using Caenorhabditis elegans
miR-39 for normalization, as previously described.7 Creati-
nine, high-sensitivity troponin T (hsTnT) and alanine amino-
transferase (ALT) were analysed at an accredited central
laboratory (ISLAB, Kuopio, Finland) using standard kits (Roche
Diagnostics, Basel, Switzerland). hsTnT was also measured at
24 h in 142 patients with samples available from both time
points. Estimated glomerular filtration rate (eGFR) was calcu-
lated from creatinine values using the Chronic Kidney Disease
Epidemiology Collaboration equation.14 Arterial blood lactate
was analysed locally.
Associations between miR-423-5p, other biomarkers, clini-
cal data, and 90 day all-cause mortality were analysed using
SPSS statistical software version 23 (IBM Corp., Armonk, NY,
USA). Two-sided P < 0.05 was considered statistically
significant. Mann–Whitney U-test was used to determine
the statistical significance of between-group differences in
miR-423-5p levels. Associations between continuous
variables with non-normal distributions were assessed using
Spearman correlations. Differences in mortality were
assessed by comparing Kaplan–Meier survival curves using
the log-rank test. To test for the independent association of
miR-423-5p level above median at baseline with 90 day mor-
tality, a multivariable Cox regression model was constructed
with 90 day all-cause mortality as the dependent variable.
In the multivariable Cox regression model, adjustments were
made for variables included in the CardShock risk score,2
hsTnT, and ALT at baseline. Nested Cox regression models
containing (i) CardShock risk score variables or (ii) CardShock
risk score variables and miR-423-5p level above median were
compared using the likelihood ratio test. General linear
model was used to analyse the independent predictors of
miR-423-5p level using miR-423-5p as the dependent
variable. To normalize the distribution and the residuals,
miR-423-5p was log transformed for this analysis.
Results
The mean age in the study cohort was 66 years, and 26%
were women. Average mean arterial pressure was 57 (SD
11) mmHg. The main aetiology of CS was acute coronary
syndrome (ACS) (78%). Non-ACS causes consisted mainly
of worsening chronic heart failure (10%), valvular and other
mechanical causes (7%), and myocarditis (2%). The 90 day
all-cause mortality was 42%. miR-423-5p level at baseline
was two-fold higher in non-survivors compared with survi-
vors {median 0.008 arbitrary units (AU) [interquartile range
(IQR) 0.003–0.017] vs. 0.004 AU [IQR 0.002–0.009],
P = 0.003}. Moreover, patients with miR-423-5p level above
median had higher levels of lactate and ALT, lower eGFR,
and lower cardiac index at baseline than had patients with
miR-423-5p level below median (Table 1). There was a
modest positive correlation between baseline miR-423-5p
level and lactate [Spearman correlation coefficient (rs) = 0.28,
P < 0.001], ALT (rs = 0.38, P < 0.001), and creatinine
(rs = 0.19, P = 0.01).
To determine independent predictors of miR-423-5p
level, a general linear model was constructed using miR-
423-5p as the dependent variable. In this model, indepen-
dent predictors of miR-423-5p level were ACS aetiology
(coefficient B = 2.7 for ACS aetiology, P = 0.001), ALT
(B = 0.03 for 100 IU/L increase, P = 0.02), and blood lactate
at baseline (B = 0.03 for 1 mmol/L increase, P = 0.02). To
explore whether miR-423-5p level at baseline was associ-
ated with the extent of developing myocardial injury, we
tested for correlation between miR-423-5p and hsTnT at
baseline and 24 h. A modest correlation between miR-
423-5p at baseline and hsTnT at 24 h was found in ACS
(rs = 0.27, P = 0.003) but not in non-ACS patients (rs = 0.04,
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P = 0.87). No correlation was found between miR-423-5p
and hsTnT at baseline.
Comparing Kaplan–Meier curves, we found that patients
with miR-423-5p level above median had higher 90 day
all-cause mortality (Figure 1A). In Cox regression analysis,
miR-423-5p level above median was associated with
90 day all-cause mortality with an unadjusted hazard ratio
(HR) of 1.9 (95% confidence interval 1.2–3.1, P = 0.006).
Adjusting for the variables included in the CardShock risk
score2 (i.e. age, prior myocardial infarction or coronary by-
pass grafting, altered mental status at presentation, ACS
aetiology, left ventricular ejection fraction, lactate, and esti-
mated glomerular filtration fraction), hsTnT, and ALT at
baseline, miR-423-5p level above median was indepen-
dently associated with 90 day all-cause mortality (HR 1.9,
95% CI 1.2-3.2, P = 0.01, Figure 1B). Lactate, prior myocar-
dial infarction or coronary bypass grafting, and left ventric-
ular ejection fraction also independently predicted
Figure 1 (A) Kaplan–Meier survival curves for patients with miR-423-5p below (black line) and above (grey line) median at baseline. (B) Hazard ratios
and 95% confidence intervals (in parentheses) of the multivariable model including CardShock risk score variables and other variables associated with
miR-423-5p level. ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; eGFR, estimated glomerular filtration rate; HR, hazard ratio;
hsTnT, high-sensitivity troponin T; LV, left ventricle; MI, myocardial infarction. *P < 0.05 **P = 0.001.
Table 1 Clinical and biochemical characteristics of patients stratified by miR-423-5p level at baseline
All (n = 179)
miR-423-5p below
median (n = 90)
miR-423-5p above
median (n = 89) P-value
Age, years 66 ± 12 66 ± 12 66 ± 12 0.8
Male, n (%) 132 (74) 67 (74) 65 (73) 0.9
Mean arterial pressure, mmHg 57 ± 11 56 ± 10 57 ± 11 0.5
Previous MI or CABG, n (%) 46 (26) 23 (26) 23 (26) >0.9
Altered mental status at
presentation, n (%)
118 (67) 57 (64) 61 (69) 0.5
ACS aetiology, n (%) 143 (80) 69 (77) 74 (83) 0.4
LVEF, % 33 ± 14 33 ± 14 33 ± 14 0.9
eGFR, mL/min/1.73 m2 63 ± 30 70 ± 30 56 ± 27 0.002
Lactate, mmol/L 2.7 (1.7–5.8) 2.4 (1.4–3.5) 3.7 (2.0–6.7) 0.001
ALT, IU/L 44 (4–54) 35 (16–66) 68 (27–133) <0.001
NT-pro-BNP, ng/L 2710 (586–9434) 2889 (900–7634) 2581 (407–10 118) 0.7
hsTnT, ng/L 2190 (388–5418) 1635 (402–5127) 2565 (366–6870) 0.3
hsTnT at 24 h, ng/L 3848 (943–12 756) 2599 (727–10 310) 5217 (1575–17 019) 0.02
Cardiac index,a L/min/m2 2.2 ± 0.9 2.4 ± 1.0 1.8 ± 0.6 0.04
Results are presented as mean ± SD for normally distributed variables, medians, and interquartile ranges for non-normally distributed var-
iables and as n (%) for categorical variables. ACS, acute coronary syndrome; ALT, alanine aminotransferase; CABG, coronary artery bypass
graft; CI, cardiac index; eGFR, estimated glomerular filtration rate; hsTnT, high-sensitivity troponin T; LVEF, left ventricular ejection frac-
tion; MI, myocardial infarction; NT-pro-BNP, N-terminal fragment of pro-B-type natriuretic peptide.
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mortality. Comparing nested Cox regression models con-
firmed that the addition of miR-423-5p level above median
as a variable to the CardShock risk score model improved
the model’s predictive power on 90 day all-cause mortality
(χ2 = 7.2, P = 0.007, for comparison of nested models;
c-index for the Cox model with miR-423-5p level above
median = 0.790 and without = 0.776).
We also explored the association of miR-423-5p level with
the aetiology of CS. Comparing Kaplan–Meier curves, we
found that miR-423-5p level above median was associated
with higher mortality in both ACS (log-rank test P = 0.04)
and non-ACS (log-rank test P = 0.03) patients. Patients with
ACS had higher miR-423-5p level than had non-ACS patients
[median 0.005 AU (IQR 0.003–0.016) vs. 0.003 AU (IQR
0.001–0.008), P = 0.01].
Conclusions
This is the first study to show an association between levels
of a circulating microRNA and mortality in CS. The main find-
ings are as follows. First, above median level of miR-423-5p
predicted 90 day all-cause mortality independently of
established risk factors of CS. Second, the association of
above median level of miR-423-5p with 90 day all-cause
mortality was independent of the aetiology of CS. Third,
miR-423-5p level and correlations with hsTnT at 24 h differed
between ACS and non-ACS patients.
It is interesting to note that miR-423-5p behaved differ-
ently in ACS and non-ACS patients. The origin and mecha-
nisms leading to elevated levels of circulating microRNAs
are not fully elucidated.15 miR-423-5p has been shown to
be enriched in the coronary circulation of heart failure
patients,16 suggesting a cardiac source. Circulating levels of
miR-423-5p have also been shown to be elevated early in
acute myocardial infarction.17,18 However, as microRNAs are
generally not considered to be very tissue specific, it may
be hypothesized that circulating miR-423-5p could have other
sources as well. As the observed correlations between
miR-423-5p, lactate, ALT, and creatinine were weak, there
are probably other factors affecting the level of miR-423-5p
as well. Given the association of miR-423-5p with low cardiac
index and high lactate levels, the possibility that increased
miR-423-5p levels are a marker of organ hypoperfusion in
general and shock from any cause rather than being
specifically associated with CS cannot be excluded.
This study has some limitations. The observation that
miR-423-5p level above median was associated with a lower
cardiac index is limited by the small proportion of patients
(21%) with pulmonary artery catheters. Invasive haemody-
namic monitoring is not routinely advocated,1 and we believe
that our cohort reflects current clinical practice. It should be
noted that CS is a complex syndrome, and although mortality
analyses were adjusted for all relevant variables available,
residual confounding may be present. Furthermore, these
findings should be interpreted as preliminary and need to
be confirmed in another CS population with mixed etiologies.
In conclusion, miR-423-5p level above median at baseline
is associated with markers of hypoperfusion and seems to
predict 90 day mortality independently of established risk
factors in CS.
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